

Molecular etiology of arthrogryposis in multiple families of mostly Turkish origin

Yavuz Bayram,¹ Ender Karaca,¹ Zeynep Coban Akdemir,¹ Elif Ozdamar Yilmaz,² Gulsen Akay Tayfun,³ Hatip Aydin,⁴ Deniz Torun,⁵ Sevcan Tug Bozdogan,⁶ Alper Gezdirici,⁷ Sedat Isikay,⁸ Mehmed M. Atik,¹ Tomasz Gambin,¹ Tamar Harel,¹ Ayman W. El-Hattab,⁹ Wu-Lin Charng,¹ Davut Pehlivan,¹ Shalini N. Jhangiani,¹⁰ Donna M. Muzny,¹⁰ Ali Karaman,¹¹ Tamer Celik,¹² Ozge Ozalp Yuregir,¹³ Timur Yildirim,¹⁴ Ilhan A. Bayhan,¹⁴ Eric Boerwinkle,^{10,15} Richard A. Gibbs,¹⁰ Nursel Elcioglu,³ Beyhan Tuysuz,² and James R. Lupski^{1,10,16,17}

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. ²Department of Pediatric Genetics, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey.

³Department of Pediatric Genetics, Marmara University School of Medicine, Istanbul, Turkey. ⁴Department of Medical Biology, Namik Kemal University Medical Faculty, Tekirdag, Turkey. ⁵Department of Medical Genetics, Gulhane Military Medical Academy, Ankara, Turkey. ⁶Department of Medical Genetics, Mersin University Faculty of Medicine, Mersin, Turkey. ⁷Department of Medical Genetics, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey. ⁸Department of Pediatric Neurology, Kahramanmaraş Sutcu Imam University, Kahramanmaraş, Turkey. ⁹Division of Clinical Genetics and Metabolic Disorders, Department of Pediatrics, Tawam Hospital, Al-Ain, United Arab Emirates. ¹⁰Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA. ¹¹Center of Genetics Diagnosis, Zeynep Kamil Women's and Children's Diseases Training and Research Hospital, Istanbul, Turkey. ¹²Department of Pediatric Neurology, Adana Numune Research and Education Hospital, Adana, Turkey. ¹³Genetics Diagnosis Center, Seyhan Practice Center, Adana Numune Training and Research Hospital, Adana, Turkey. ¹⁴Orthopaedic and Traumatology Department, Baltalimani Bone Diseases Training and Research Hospital, Istanbul, Turkey. ¹⁵Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA. ¹⁶Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. ¹⁷Texas Children's Hospital, Houston, Texas, USA.

BACKGROUND. Arthrogryposis, defined as congenital joint contractures in 2 or more body areas, is a clinical sign rather than a specific disease diagnosis. To date, more than 400 different disorders have been described that present with arthrogryposis, and variants of more than 220 genes have been associated with these disorders; however, the underlying molecular etiology remains unknown in the considerable majority of these cases.

METHODS. We performed whole exome sequencing (WES) of 52 patients with clinical presentation of arthrogryposis from 48 different families.

RESULTS. Affected individuals from 17 families (35.4%) had variants in known arthrogryposis-associated genes, including homozygous variants of cholinergic γ nicotinic receptor (*CHRN*, 6 subjects) and endothelin converting enzyme-like 1 (*ECEL1*, 4 subjects). Deleterious variants in candidate arthrogryposis-causing genes (fibrillin 3 [*FBN3*], myosin Ixa [*MYO9A*], and pleckstrin and Sec7 domain containing 3 [*PSD3*]) were identified in 3 families (6.2%). Moreover, in 8 families with a homozygous mutation in an arthrogryposis-associated gene, we identified a second locus with either a homozygous or compound heterozygous variant in a candidate gene (myosin binding protein C, fast type [*MYBPC2*] and vacuolar protein sorting 8 [*VPS8*], 2 families, 4.2%) or in another disease-associated genes (6 families, 12.5%), indicating a potential mutational burden contributing to disease expression.

CONCLUSION. In 58.3% of families, the arthrogryposis manifestation could be explained by a molecular diagnosis; however, the molecular etiology in subjects from 20 families remained unsolved by WES. Only 5 of these 20 unrelated subjects had a clinical presentation consistent with amyoplasia; a phenotype not thought to be of genetic origin. Our results indicate that increased use of genome-wide technologies will provide opportunities to better understand genetic models for diseases and molecular mechanisms of genetically heterogeneous disorders, such as arthrogryposis.

FUNDING. This work was supported in part by US National Human Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) grant U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics, and US National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS058529 to J.R. Lupski.

Conflict of interest: J.R. Lupski has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, has stock options in Lasergen Inc., and is a coinventor on multiple US and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing offered in the Baylor Miraca Genetics Laboratory (BMGL, <http://www.bmgl.com/BMGL/Default.aspx>). R.A. Gibbs is interim Chief Scientific Officer of BMGL, and J.R. Lupski is on the Scientific Advisory Board of BMGL.

Submitted: August 27, 2015; **Accepted:** November 25, 2015.

Reference information: *J Clin Invest.* 2016;126(2):762–778. doi:10.1172/JCI84457.

Introduction

Arthrogryposis, also known as arthrogryposis multiplex congenita, is clinically defined as congenital joint contractures or movement restriction in multiple body areas. It should be distinguished from isolated congenital contractures that affect a single joint such as congenital clubfoot deformity or dislocated hip. Arthrogryposis is a symptom rather than a specific diagnosis and occurs in between 1/3,000–1/5,000 live births (1). To date, more

than 400 disorders have been described that include arthrogryposis as an endophenotype (2).

In general, arthrogryposis occurs by virtue of a secondary effect of decreased fetal joint mobility (i.e., fetal akinesia). Disorders leading to fetal akinesia can result from abnormalities of the CNS, neuromuscular system, skeletal system, and connective and cartilage tissue disturbances. Maternal diseases or environmental factors such as intrauterine space limitations, maternal exposures to drugs or chemicals, compromise of blood supply to the fetus, and metabolic disturbances may also lead to fetal akinesia (2–4).

Distal arthrogryposis (DA) syndromes describe a heterogeneous subgroup of arthrogryposis characterized by multiple congenital contractures that mainly involve the distal parts of the upper and lower limbs without a primary neuromuscular disease (5, 6). According to different classifications, up to 19 clinical subtypes of DA were described (2, 5, 7). In most cases (~50%), mutations in genes encoding contractile proteins of skeletal muscles were shown to cause the DA phenotype, which consists of nonprogressive congenital contractures of the joints located at distal limbs (8–12). Genes determined to contribute to the molecular etiology of DA include *FBN2*, *MYBPC1*, *MYH3*, *MYH8*, *PIEZ02*, *TNNI2*, *TNNT3*, and *TPM2*. Recently, homozygous *ECEL1* mutations, most representing loss-of-function alleles and resulting in absence of the encoded protein, were identified in patients with DA type 5D (OMIM 615065). In this group of DA, patients presented a distinctive clinical presentation with severe camptodactyly of the hands and wrists; milder camptodactyly of toes; limited knee flexion; talus and/or varus deformity of the ankles; ptosis and distinctive facial features of round-shaped, mask-like faces; high-arched eyebrows; bulbous noses; and micrognathia (13, 14).

Another phenotypically and genetically heterogeneous subgroup of arthrogryposis is multiple pterygium syndrome (MPS), which is characterized by multiple pterygia, scoliosis, and congenital contractures of the limbs. MPS has both lethal (OMIM 253290) and nonlethal (Escobar variant) (OMIM 265000) types. Although most of the MPS cases were reported with a pattern of autosomal-recessive inheritance (15), autosomal-dominant transmission was also observed in a few cases (16–18). While homozygous and compound heterozygous mutations of *CHRNG* (19, 20) were associated with both lethal and nonlethal types of MPS, mutations of *CHRND* (21) and *CHRNA1* (21) are also responsible for lethal MPS. Recently, homozygous mutations in *RYR1* (22) and autosomal-dominant inheritance with *MYH3* mutations were reported in MPS patients (23).

Genetic causes of disorders with arthrogryposis include single gene mutations, chromosomal abnormalities, and mitochondrial defects (2, 24, 25). To date, variants in more than 220 genes with different modes of inheritance have been associated with arthrogryposis disorders (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI84457DS1), but in the considerable majority of these disorders, the underlying molecular etiology remains unknown. To better understand the genetics of arthrogryposis and identify potential novel molecular etiologies underlying this genetically heterogeneous group of diseases, we applied whole exome sequencing (WES) to a cohort of 52 patients from 48 families, including 22 with reported consanguinity yet with different clinical subtypes of arthrogryposis.

Results

The approach used for gene identification is outlined in Supplemental Figure 1. We first assessed WES data of all patients for rare variants in known arthrogryposis genes before investigating for potential novel genes. A list of known genes (Supplemental Table 1) was constructed from multiple online database resources (<http://www.omim.org/>, <http://www.mnglabs.com/tests/>, <http://www.ncbi.nlm.nih.gov/pubmed>) or abstracted from recently published articles (2, 3, 26–35). Deleterious variants in the known arthrogryposis-associated genes were identified in 17 of 48 (35.4%) unrelated families (Table 1). To the best of our knowledge, specific rare variants in known genes were not reported previously in 12 of 17 families, and 3 of those (*CENPJ*, *GBE1*, and *IDS*) were associated with traits suggesting phenotypic expansion (Table 1). In 3 families (6.2%), we identified deleterious variants in 3 novel genes, including *FBN3*, *MYO9A*, and *PSD3*. In 8 families (16.7%), we describe a second homozygous or compound heterozygous variant in a novel gene or in another known gene, in addition to the homozygous variant in a known gene (vacuolar protein sorting 8 [*VPS8* (novel)] with *POLR3A*, *MYBPC2* [novel] with *GPR126*, *CHRNG* with *ERCC2*, *COL6A3* with *BICD2*, *LIFR* with *PI4KA*, *LIFR* with *MYH14*, *MYO18B* with *MYH7B*, and *RIPK4* with *LMNA*) (Table 2). Identified variants in these apparently solved cases with a molecular diagnosis obtained from WES and family pedigrees are provided in Supplemental Table 2 and Supplemental Figure 2, respectively.

While 58.3% of families manifesting arthrogryposis could be explained by a molecular diagnosis identified on WES, subjects from 20 families remained unsolved, in that no definitive molecular diagnosis could be concluded. Since amyoplasia is the most common form of arthrogryposis that appears to be a sporadic nongenetic condition, we have carefully reexamined the clinical information of the patients in the 20 unsolved families. Five of these indeed match the clinical diagnosis of amyoplasia. However, the remaining 15 probands had different types of arthrogryposis-related disorders, such as spinal muscular atrophy, DA, MPS, and other unspecified multiple joint contractures. There were no disease-causing variants in known genes in these patients, and we could not identify any variant in a novel gene with convincing supporting data. Thus, we concluded that 5/20 unsolved cases had a clinical presentation consistent with amyoplasia, providing a possible explanation as to why no molecular diagnosis was achieved, at least in these cases.

We identified 1 homozygous stop-gain (in 2 families) and 2 homozygous missense mutations in *ECEL1* in 4 unrelated consanguineous families, one of which is an Arab family (HOU2530). In 2 unrelated Turkish families (HOU1530 and HOU2432) with DA, we identified the same homozygous stop-gain mutation in *ECEL1* (c.1147C>T; p.Gln383X). In addition, for 2 unrelated consanguineous families (HOU2460 and HOU2530), we detected 2 different homozygous missense *ECEL1* mutations (c.2023G>A; p.Ala675Thr and c.1210C>T; p.Arg404Cys, respectively [Figure 1A]).

From a clinical perspective, patient BAB3934 from family HOU1530 had contractures of both hands and feet, limited knee flexion, and bilateral hip dislocation. Electromyography (EMG) study revealed mild myogenic involvement. The subject had a flat and round-shaped face, high-arched eyebrows, and a bulbous and upturned nose. Clinical findings of the patient BAB6500 from

Table 1. Patients with a rare mutation in a single known gene

Pedigree	Patient	Clinical findings	Gene	Variant	Novel variant	Zyg	Gene-Phenotype relationship(s)
HOU1684	BAB4104	Contractures of elbows and knees, camptodactyly, syndactyly of left toes 3 and 4, overlapping fingers and toes, rocker-bottom feet, bilateral ptosis, micrognathia, short and webbed neck, hypospadias, and bilateral cryptorchidism	<i>CHRN</i>	c.256C>T; p.Arg86Cys	Yes	Hom	
HOU2430	BAB6498	Contractures of hands, elbows, and knees; multiple pterygiums; short neck; TEV; DPF; small mouth; and decayed teeth	<i>CHRN</i>	c.753_754 delCT; p.Val253fs	No	Hom	
HOU2606	BAB7080	Contractures of hands, elbows, and knees; multiple pterygiums; rocker-bottom feet; DPF; micrognathia; small mouth; ECHO: Atrial septal defect and tricuspid insufficiency	<i>CHRN</i>	c.241C>T; p.Gln81X	Yes	Hom	MPS, lethal type (OMIM 253290); Escobar syndrome (OMIM 26500)
HOU2331	BAB6209	Contractures of hands, elbows, and knees; multiple pterygiums; talipes valgus; small and low-set ears; micrognathia; and ambiguous genitalia	<i>CHRN</i>	c.715C>T; p.Arg239Cys	No	Hom	
HOU2607	BAB7083	Contractures of elbows and knees, short neck, camptodactyly, TEV, micrognathia, and prominent ears	<i>CHRN</i>	c.715C>T; p.Arg239Cys	No	Hom	
HOU1530	BAB3934	Severe flexion contracture of knees, camptodactyly, normal feet, hip dislocation, capillary hemangioma, and EMG: mild myogenic lesions	<i>ECEL1</i>	c.1147C>T; p.Gln383X	Yes	Hom	
HOU2432	BAB6500	Contractures of hands, hip-joint dysplasia, talipes valgus, facial dysmorphic features with a mask-like whistling appearance, and short neck	<i>ECEL1</i>	c.1147C>T; p.Gln383X	Yes	Hom	
HOU2460	BAB6608	Contracture of elbows, camptodactyly, scoliosis, ptosis, flat and mask-like face, high-arched eyebrows, low-set ears, micrognathia, and cryptorchidism	<i>ECEL1</i>	c.2023G>A; p.Ala675Thr	No	Hom	DA type 5D (OMIM 615065)
HOU2530	BAB6827	Severe camptodactyly, hip dislocation, hypotonia, right TEV, developmental delay, thin corpus callosum on cranial MRI, mask-like face, high-arched eyebrows, bulbous and upturned nose, low-set ears, micrognathia, nephrocalcinosis, and cryptorchidism	<i>ECEL1</i>	c.1210C>T; p.Arg404Cys	No	Hom	
HOU1522	BAB3903	Contractures of both hands, TEV, high-arched feet, and contracture of toes	<i>COL6A2</i>	c.289G>A; p.Ala97Thr	Yes	Hom	Myosclerosis, congenital (OMIM 255600); Bethlem myopathy (OMIM 158810); Ullrich congenital muscular dystrophy (OMIM 254090)
HOU1529	BAB3931	Contractures of elbows, ulnar deviation of hands, retromicrognathia, high-arched palate, crowded and decayed teeth, low-set ears, delayed bone age, TEV, and abnormal scar formation on left foot	<i>CENPJ</i> ^a	c.763A>G; p.Thr255Ala	Yes	Hom	Microcephaly 6, primary, autosomal recessive (OMIM 608393); SCKL 4 (OMIM 613676)
HOU1539	BAB3955	Flexion contractures of hands, rocker-bottom feet, delayed neuromotor development, growth retardation, hypotonia, seizures, low-set ears, high-arched palate, laryngomalacia, AP-US: Hepatosteatosis and nephrocalcinosis, EEG: Hypsarrhythmia, and EMG: Anterior horn cell involvement of spinal cord. Died at 1.5 years. Clinical diagnosis: Spinal muscular atrophy	<i>IDS</i> ^A	c.613G>A; p.Ala205Thr	Yes	Hem	MPS2 (OMIM 309900)
HOU1540	BAB3958	Severe contraction of knees, elbow contractures, ulnar deviation of hands, rocker-bottom feet, talipes valgus, short neck, and scoliosis	<i>TPM2</i>	c.180T>G; p.Tyr60X	Yes	Hom	DA type 1A (OMIM 108120); DA type 2B (OMIM 601680); Nemaline myopathy 4, AD (OMIM 609285)
HOU1541	BAB3960	Joint contractures, hypotonia, cleft palate, micrognathia, short neck, tall vertebral bodies on X-ray, mild talipes equinovarus, and pelvicilectasis	<i>GBE1</i> ^A	c.776C>G; p.Ala259Gly	Yes	Hom	Glycogen storage disease IV (OMIM 232500); Polyglucosan body disease, adult form (OMIM 263570)
HOU2114	BAB5449	Elbow contractures, developmental delay, recurrent infections, swallowing difficulty, contractures of the facial muscles, chubby cheeks, blepharophimosis, epicanthal folds, synophrys, long eyelashes, hirsutism, prominent and wide nasal root, high-arched palate, small mouth, and severe dental caries	<i>CRLF1</i>	c.984_985insG; p.Ser328fs	Yes	Hom	Cold-induced sweating syndrome 1 (OMIM 272430)
HOU2683	BAB7305	Severe contraction of knees, contractures of elbows and hands, joint laxity, muscle hypoplasia, axillary and popliteal pterygium, delayed motor milestones, and ECHO: Localize septal hypertrophy	<i>FHL1</i>	c.29C>G; p.Ser10Cys	Yes	Hem	Emery-Dreifuss muscular dystrophy 6, X-linked (OMIM 300696); Myopathy, reducing body, X-linked (OMIM 300717)
HOU2789	BAB7707	Contractures of elbows and hands, patella agenesis, short stature, pectus carinatum, epiphyseal and metaphyseal dysplasia, mild TEV, and delayed motor milestones	<i>SLC26A2</i>	c.2057G>A; p.Cys686Tyr	Yes	Hom	Diastrophic dysplasia (OMIM 222600); Atelosteogenesis 2 (OMIM 256050); Achondrogenesis 1B (OMIM 600972); Epiphyseal dysplasia, multiple, 4 (OMIM 226900)

^aGenes in which variant alleles were associated with traits suggesting phenotypic expansion. AD, autosomal dominant; AP-US, abdominopelvic ultrasound; DPF, downslanting palpebral fissures; ECHO, echocardiogram; EEG, electroencephalography; Hem, hemizygous; Hom, homozygous; TEV, talipes equinovarus; Zyg, zygosity.

Table 2. Clinical and genotype summary of the patients with potential oligogenic or mutational burden model

Pedigree	Patient	Clinical findings	Gene	Variant	Zyg	Gene-Phenotype relationship(s)
HOU2163	BAB5611	Terminated pregnancy at 24 weeks of gestation. Fetal autopsy: Joint contractures, depressed nasal root, micrognathia, lung hypoplasia, short thorax, and rocker-bottom feet	<i>CHRN</i>	c.715C>T; p.Arg239Cys	Hom	MPS, lethal type (OMIM 253290), Escobar syndrome (OMIM 26500)
			<i>ERCC2</i>	c.1775G>A; p.Arg592His	Hom	COFS type 2 (OMIM 610756)
HOU2278	BAB6018	Contractures of knees and elbows, developmental delay, hip dislocation, torticollis, scoliosis, pes planus, micrognathia, anteverted nostrils, high-arched palate, prominent ears, brain MRI: ventricular dilatation and brain stem atrophy	<i>COL6A3</i>	c.7720delC; p.Leu2574fs	Hom	Bethlem myopathy (OMIM 158810); Ullrich congenital muscular dystrophy (OMIM 254090)
	BAB6019	Mild joint contractures, developmental delay, hip dislocation, scoliosis, flat occiput, micrognathia, anteverted nostrils, high-arched palate, and macrotia	<i>BID2</i>	c.1477C>T; p.Arg493Cys	Hom	Spinal muscular atrophy, lower extremity predominant, 2, AD (OMIM 615290)
HOU2332	BAB6212	Unclassified DA, narrow thorax, polyhydramnios during pregnancy, and postnatal death	<i>GPR126</i>	c.19C>T; p.Arg7X	Hom	Recently reported in 3 families with lethal arthrogryposis multiplex congenita (29)
			<i>MYBPC2</i>	c.707C>T; p.Thr236Ile	Het	
			<i>MYBPC2</i>	c.764G>C; p.Ser255Thr	Het	Not reported in any Mendelian disorder
HOU2682	BAB7302	Contractures of distal joints, delayed neuromotor development, hypotony, swallowing difficulty, pyloric stenosis, tibia vara, enlarged metaphyses, and multiple milia	<i>LIFR</i>	c.274C>T; p.Gln92X	Hom	SWS (OMIM 601559)
			<i>PI4KA</i>	c.1768G>A; p.Asp590Asn	Het	Recently associated with perisylvian polymicrogyria, cerebellar hypoplasia and arthrogryposis (33)
			<i>PI4KA</i>	c.1901T>C; p.Met634Thr	Het	
HOU2616	BAB7125	Contractures of hands and elbows, severe developmental delay, swallowing difficulty, high-arched palate, pectus excavatum, scoliosis, hypertrophy in calf muscles, and mild mitral valve insufficiency	<i>LIFR</i>	c.1789C>T; p.Arg597X	Hom	SWS (OMIM 601559)
			<i>MYH14</i>	c.4594C>T; p.Arg1532Trp	Het	Peripheral neuropathy, myopathy, hoarseness, and hearing loss (OMIM 614369); deafness, autosomal dominant 4A (OMIM 600652)
			<i>MYH14</i>	c.5887C>T; p.Arg1963Cys	Het	
HOU2620	BAB7140	Preterm birth, delayed motor milestones, contractures of hands and elbows, webbed neck, high-grade rotoscoliosis, congenital ptosis, vertebral segmentation and fusion defects	<i>MYO18B</i>	c.6322C>T; p.Arg2108X	Hom	Recently reported in 2 families with Klippel-Feil anomaly, myopathy, and DA (32)
			<i>MYH7B</i>	c.3950G>A; p.Arg1317Gln	Hom	Reported in a family with congenital myopathy and cardiomyopathy (39)
HOU2621	BAB7143	Contractures of hands and feet (DA), delayed motor milestones, myotonia, microcephaly, difficulty in swallowing solid food, constipation, congenital ptosis, hip dislocation, TEV, ECHO: Bicuspid aorta, MRI: Cerebellar vermis hypoplasia and Dandy-Walker malformation	<i>VPS8</i>	c.3130G>A; p.Val1044Ile	Hom	Not reported in any Mendelian disorder
			<i>POLR3A</i>	c.3388G>A; p.Val1130Ile	Hom	Leukodystrophy, hypomyelinating, 7 (OMIM 607694)
HOU2791	BAB7713	Contractures of hands and feet, TEV, hypotony, myopathic face, feeding difficulty, EMG: myopathia, ECHO: dilated cardiomyopathy	<i>RIPK4</i>	c.1681G>A; p.Val561Met	Hom	Popliteal pterygium syndrome 2, lethal type (OMIM 263650)
			<i>LMNA</i>	c.350A>G; p.Lys117Arg	Hom	Cardiomyopathy, dilated, 1A (OMIM 115200); Emery-Dreifuss muscular dystrophy 3, AR (OMIM 181350); Heart-hand syndrome, Slovenian type (OMIM 610140); Muscular dystrophy, congenital (OMIM 613205); Muscular dystrophy, limb-girdle, type 1B (OMIM 159001)

AD, autosomal dominant; AR, autosomal recessive; ECHO, echocardiogram; Het, heterozygous; Hom: homozygous; TEV, talipes equinovarus.

family HOU2432 included flexion contractures of both hands, hip-joint dysplasia, talipes valgus, and also a unique facial dysmorphic feature of a flat and round-shaped face with a mask-like whistling appearance (Figure 1B). After a careful search within the kindred in HOU2432, a third-degree cousin of BAB6500 was also found to have DA. The affected cousin and his parents were analyzed by

Sanger sequencing, and the cousin was also found to be homozygous while the parents were heterozygous carriers for the same variant identified in BAB6500 (Figure 1A).

Individual BAB6608 from family HOU2460 had contractures of the elbows, camptodactyly, scoliosis, ptosis, a flat and mask-like face, high-arched eyebrows, low-set ears, micrognathia,

and cryptorchidism. Individual BAB6827 from family HOU2530 had severe camptodactyly of the hands, bilateral hip dislocation, right talipes equinovarus, hypotonia, developmental delay, cryptorchidism, nephrocalcinosis detected in the sonogram of the abdomen, and thin corpus callosum. He also had distinctive facial features of a mask-like face, high-arched eyebrows, a bulbous and upturned nose, low-set ears, and micrognathia (Figure 1B). Moreover, given the consanguinity between the parents in these 4 families, we examined the absence of heterozygosity (AOH) regions in all probands with *ECEL1* mutations. Haplotype block analysis based on single nucleotide polymorphism data culled from exome sequencing (i.e., B-allele frequency) revealed that the maximal shared region of AOH in the 4 families was approximately 840 Kb on the distal long arm of chromosome 2, including the *ECEL1* gene. Since there are 3 different mutations, the actual haplotypes in these AOH blocks are presumed to differ (Figure 1C).

In 6 patients, we identified 4 different homozygous variants in *CHRNG*, a known causal gene for lethal and nonlethal MPS. The identified variants include 1 stop-gain (c.241C>T; p.Gln81X), 1 frameshift deletion (c.753_754delCT; p.Val253Alafs), 1 missense mutation (c.256C>T; p.Arg86Cys), and 1 recurrent missense mutation (c.715C>T; p.Arg239Cys), which was observed in 3 patients from reportedly unrelated families (Figure 2A). The common findings in these patients were prenatally detected restriction of movements; craniofacial dysmorphisms, including down-slanting palpebral fissures, low-set ears, and micrognathia; and multiple contractures of the limbs (Figure 2B). The distribution of *CHRNG* mutations detected in our study is shown in Figure 2, C and D. Two of the identified *CHRNG* mutations have not been reported, while the other mutations, including the recurrent mutation, have been reported previously in MPS patients (20, 36). In 1 of 3 patients with the same homozygous *CHRNG* mutation (BAB5611), we additionally identified another homozygous deleterious mutation in a different arthrogryposis gene, *ERCC2* (c.1775G>A; p.Arg592His) (Figure 2A). *ERCC2* is a known gene for an arthrogryposis related disorder, cerebrooculofacioskeletal syndrome (COFS) type 2 (OMIM 610756), and 2 other allelic disorders (trichothiodystrophy [OMIM 601675] and xeroderma pigmentosum, group D [OMIM 278730]).

Other identified variants in known genes are delineated in Tables 1 and 2. Although 17 of these families are singleton cases with different mutations in different known genes (Table 1), we observed 8 families with an arthrogryposis gene mutational load, as we observed in family HOU2163 with *CHRNG* and *ERCC2* mutations (Table 2). These families have another homozygous or compound heterozygous predicted deleterious variant in an additional known gene or in a novel gene that cannot be excluded from having a potential clinical contribution because of its function in arthrogryposis formation or close interactions with known arthrogryposis gene products.

After exclusion of known genes, we examined patient genomes for novel genes, investigating all potential inheritance models. Our strategy of choosing best-candidate genes was based on function of the gene; interactions with other known arthrogryposis genes; functional prediction scores calculated by different computational algorithms (PolyPhen-2, MutationTaster, SIFT, LRT, and Phylop); review of our internal database (~4,800 exomes),

including the Turkish subpopulation (~630 exomes), or other available databases such as the 1,000 Genomes Project (<http://www.1000genomes.org>), the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP; Seattle, Washington, USA; <http://evs.gs.washington.edu/EVS/>), the Atherosclerosis Risk in Communities Study (ARIC) database (<http://drupal.cscc.unc.edu/aric/>), and the Exome Aggregation Consortium (ExAC, <http://exac.broadinstitute.org/>) databases to examine the rarity of the identified variants; and segregation in the family studied. Using this approach, we identified compound heterozygous variants in *FBN3* (c.1883C>T; p.Ser628Phe and c.8357G>A; p.Gly2786Asp) in a patient with contractions of the elbows and knees, compound heterozygous variants in *MYO9A* (c.6845G>A; p.Gly2282Glu and c.608A>G; p.Tyr203C) in a patient with multiple limb contractures, and a heterozygous missense *PSD3* variant (c.437T>C; p.Ile146Thr) in 3 affected kindred with antecubital pterygium syndrome (APS) (OMIM 178200) (Table 3).

Discussion

In our study, we define a general approach to investigate the molecular etiology underlying arthrogryposis by using WES in a patient cohort of subjects with different clinical subtypes of arthrogryposis. We identified known and novel variants in known genes and variants in potential novel candidate genes, and we provide evidence for phenotypic expansion in a few cases. Moreover, some subjects were found to have evidence for an apparent mutational load with disease-associated variants in more than one arthrogryposis gene locus and to be manifesting a more severe clinical phenotype.

The most common known arthrogryposis-associated genes identified in our cohort were *ECEL1* and *CHRNG*. While the phenotypes associated with these variants were overall consistent with those reported, some patients had novel clinical features. For instance, BAB6500 had a distinct whistling face, which is commonly observed with *MYH3* variants in Freeman-Sheldon syndrome (also known as DA type 2A) (OMIM 193700) (9). *MYH3* encodes one of the contractile proteins of skeletal muscle, while *ECEL1* mutations result in perturbed formation of the neuromuscular junction. Although developmental pathways that cause DA type 2A and DA type 5D are different, the observed whistling-face finding in an *ECEL1* mutated case not only shows the complexity of the phenotypic spectrum seen in this heterogeneous subgroup of arthrogryposis, but also underscores the limitation of clinical characterization of arthrogryposis subtypes. Patient BAB6827 had hypoplasia of the corpus callosum (HCC), in addition to DA. Given the functional and expression patterns of *ECEL1* in conjunction with neurologic findings in the patient (i.e., developmental delay and hypotonia), it is feasible to suggest that HCC may be part of the phenotype. Alternatively, there may be a yet unidentified second molecular diagnosis in this patient.

Families consistent with a potential oligogenic or mutational burden model. In patient BAB5611, a homozygous variant in *ERCC2* was detected, in addition to a homozygous variant in *CHRNG* (Figure 2A). Mutations in *ERCC2* have previously been reported in patients with COFS type 2 (37), a progressive neurodegenerative and arthrogryposis-related disorder. Vogt et al. and Morgan et al. reported a family with a homozygous missense *CHRNG* mutation; 2 affected siblings died in early infancy, while the third




Figure 1. Segregation analyses, photographs, and AOH regions of the patients with *ECEL1* mutations. (A) Detailed pedigrees of the families and their corresponding Sanger-sequencing chromatograms showing the segregation analyses. (B) Photographs of the patients. Note the whistling-face appearance of BAB6500, which is commonly observed in DA type 2A rather than *ECEL1*-associated DA type 5D. (C) AOH study of the patients based on calculated B-allele frequency data culled from WES analysis. Gray shaded areas indicate AOH regions. Note the approximately 840-Kb overlap between the AOH regions, which includes the *ECEL1* gene.




A**B****C****D**

Figure 2. Segregation results, photographs, and variant distributions of the patients with *CHRNG* mutations. (A) Pedigrees and Sanger sequencing analyses of the patients that represent the proper segregation of the WES-detected *CHRNG* variants. One of the patients with more severe phenotype (BAB5611) has another homozygous variant in a known arthrogryposis gene (*ERCC2*), which also segregates in the family. (B) Photographs of the probands showing the major clinical features, including joint contractures, multiple pterygiums, and distinct facial dysmorphism. (C and D) Schematic representations of gene and protein structures of *CHRNG* and localization of the identified variants. *Neur_chan_LBD*, neurotransmitter-gated ion-channel ligand binding domain; *Neur_chan_memb*, neurotransmitter-gated ion-channel transmembrane region.

Table 3. Patients with rare variants in a single novel candidate gene

Pedigree	Patient(s)	Clinical Findings	Gene	Variant	Zyg	Count of the identified variant in other databases				
						Internal	TGP	ARIC	ESP	ExAC
HOU2061	BAB5239	APS; Webbing across the anterior aspect of the cubital fossa and limitation of full elbow extension	PSD3	c.437T>C; p.Ile146Thr	Het	3	0	0	0	0
	BAB5242									
	BAB5246									
HOU2431	BAB6499	DA with predominantly affection of the fingers and feet, contractures of knees, camptodactyly, and TEV	MYO9A	c.6845G>A; p.Gly2282Glu	Het	1	0	0	0	0
				c.608A>G; p.Tyr203Cys	Het	3	0	1	0	27/121318 het
HOU2816	BAB7826	Severe contractures of elbows and knees, ulnar deviation of hands, TEV, and high-arched palate	FBN3	c.1883C>T; p.Ser628Phe	Het	1	0	0	0	0
				c.8357G>A; p.Gly2786Asp	Het	3	0	0	0	2/116720 het

Het, heterozygous; TEV, talipes equinovarus; TGP, 1,000 Genome Project; Zyg, zygosity.

affected sibling had nonlethal MPS (15, 20). Moreover, the same family had 4 additional cousins with nonlethal MPS phenotype and 1 deceased cousin. They concluded that, since the family represented a single observation, the significance of the clinical finding of variability of expression was unclear. We suggest that mutational burden or genetic load may contribute to clinical variability and disease severity, as has been shown in patients with Charcot-Marie-Tooth disease, wherein genetic burden contributes to phenotypic variability and complex neuropathy (38).

Variants in both *MYO18B* and *MYH7B* that were identified in BAB7140 (Figure 3A) were recently reported in 2 separate studies in patients with common clinical findings of myopathy and vertebral anomalies. Alazami et al. identified a null homozygous mutation in *MYO18B* in 2 patients from 2 unrelated families that shared a similar phenotype of Klippel-Feil anomaly, myopathy, arthrogryposis, microcephaly, and distinctive facies (32). Esposito et al. identified 2 homozygous mutations in *MYH7B* and *ITGA7* in a patient with congenital myopathy, scoliosis, and cardiomyopathy, and they concluded that a synergistic effect of these 2 mutations results in a severe phenotype (39). Our patient was a 14-year-old female and presented with more severe clinical findings, suggesting a blended phenotype (Figure 3B, Table 4, and ref. 40). The most remarkable finding in our patient was a high-grade thoracolumbar rotoscoliosis with cervical vertebral segmentation and fusion defects (Figure 3B). We compared the clinical features and identified mutations of our patient with those reported in 2 studies (Table 4). Our data strongly suggest that the mutational burden from the variants observed at the 2 genetic loci, *MYO18B* and *MYH7B*, leads to a more severe and blended phenotype of arthrogryposis and vertebral anomalies, including high-grade scoliosis and fusion defects. Additionally, AOH findings based on data culled from WES showed that both *MYO18B* and *MYH7B* variants are surrounded by AOH blocks on chromosome 22 and 20, respectively. Interestingly, the AOH data detected on chromosome 20 revealed a large AOH block (53.7 Mb) that nearly encompassed the entire chromosome (~85%), suggesting a possible uniparental disomy (Figure 3C), as has been recently reported with clinical exome sequencing for other recessive disease traits. Apart from the blended phenotype outcome of different homozygous vari-

ants, the predicted structural similarity between these 2 myosin genes leads us to speculate that variants observed in these 2 genes in the same patient may induce a more severe disruption of the myosin gene network and cause a much more severe phenotype.

In family HOU2278, which had 2 affected siblings, we identified a homozygous frameshift mutation in *COL6A3* in both patients. An additional homozygous missense mutation in *BICD2* was also observed in the more severely affected elder brother, while the sister was a heterozygous carrier for this variant (Table 2). Mutations of both *COL6A3* and *BICD2* genes have previously been reported in muscle diseases comprising arthrogryposis (41, 42). However, while homozygous mutations of *COL6A3* were reported in patients with Ullrich congenital muscular dystrophy (OMIM 254090), only heterozygous mutations of *BICD2* were reported in patients with spinal muscular atrophy, lower extremity–predominant, type 2 (OMIM 615290). Our data suggest that the more severe phenotype observed in the brother might be a consequence of the mutational burden at the 2 loci and the biallelic homozygous inheritance of the *BICD2* mutation.

In patient BAB6212, we identified a homozygous stop-gain mutation in *GPR126*, which was recently reported as a novel gene in 3 families with arthrogryposis (29). However, in this patient, WES data also revealed compound heterozygous variants in another novel gene, *MYBPC2* (Figure 4A). *MYBPC2* mutations were not previously associated with any Mendelian disease; however, mutations of *MYBPC1*, another myosin-binding protein, have previously been associated with DA type 1B (OMIM 614335) and lethal congenital contracture syndrome 4 (OMIM 614915) (10, 43). *MYBPC* proteins play structural and regulatory roles in muscle function. These proteins provide thick filament stability and modulate contractility through dynamic interactions with the head region of myosin and actin (44). Apart from these functional and molecular data, the mutated amino acids Thr236 and Ser255 are highly conserved in vertebrates (Figure 4B), and *MYBPC2* has close interactions with various known arthrogryposis genes (Figure 4C). Although *GPR126* mutations were recently associated with arthrogryposis, *MYBPC2* may also be considered as a contributory gene to the patient's phenotype due to the gene function and interactome structure of its protein product.




Figure 3. *MYO18B* and *MYH7B* variants identified in patient BAB7140. (A) The pedigree of the HOU2620 family and segregation of the *MYO18B* and *MYH7B* variants. DNA sample of the mother was not available. (B) Patient photographs and X-ray images showing the severe phenotype most probably due to the synergistic effect of 2 homozygous mutations in 2 different arthrogryposis-related genes. Note the progressive scoliosis observed in the X-rays taken in 2012 and 2014, respectively. (C) Top panel: B-allele frequency plot of the entire chromosome 22 and 20, respectively. Bottom panel: Zoomed-in views of the regions encompassing *MYO18B* and *MYH7B* indicated by blue. AOH regions are shown as gray regions. Note the large AOH block that nearly encompasses entire chromosome 20, suggesting a possible uniparental disomy.

In 2 patients (BAB7302 and BAB7125), we identified different homozygous stop-gain mutations in *LIFR*, consistent with Stuve-Wiedemann syndrome (SWS) (OMIM 601559) (45). In both cases, we also identified potential contributory variants in other known genes (Table 2). Patient BAB7302 had compound heterozygous mutations in *PI4KA*, a gene recently associated with brain malformation and arthrogryposis (33). Patient BAB7125 had compound heterozygous variants in *MYH14* (Table 2), which encodes a member of the nonmuscle myosin II family of ATP-dependent molecular motors that interact with cytoskeletal actin and regulate cytokinesis, cell motility, and cell polarity (46). Heterozygous mutations

of *MYH14* were reported in a family with a complex phenotype of peripheral neuropathy, myopathy, hoarseness, and hearing loss (47). Our patient was a 15-month-old male and had severe developmental delay, multiple joint contractures, pectus excavatum, scoliosis, hypertrophy in calf muscles, and mild mitral valve insufficiency. Although our patient had a normal hearing test and creatine kinase level, the neurologic findings and calf enlargement, which is a typical clinical feature in neuromuscular diseases, suggest that the compound heterozygous mutations of *MYH14*, in addition to *LIFR* homozygous mutation, may contribute to the severe phenotype observed in our patient due to a potential mutational burden effect.

Table 4. Comparison of the genotype and clinical findings in patient BAB7140 harboring *MYO18B* and *MYH7B* mutations with those of recently reported patients that represent similar findings

	Alazami et al. (ref. 32)		Esposito et al. (ref. 39)		Present study
Genotype	Patient 1	Patient 2	Patient 3		BAB7140
Identified gene(s)	<i>MYO18B</i>	<i>MYO18B</i>	<i>MYH7B</i>	<i>ITGA7</i>	<i>MYO18B</i>
Identified variant(s)	p.Ser2302X	p.Ser2302X	p.Arg890Cys	p.Glu882Lys	p.Arg2108X
Variant type	Nonsense	Nonsense	Missense	Missense	Nonsense
Zygosity	Homozygous	Homozygous	Homozygous	Homozygous	Homozygous
Clinical history					
Ethnic origin	Arab	Arab	Italian		Turkish
Consanguinity	Yes	Yes	Yes		Yes
Sex	Male	Female	Female		Female
Premature delivery	Yes	No	N/A		Yes
Delayed motor development	Yes	Yes	Yes		Yes
Hypotonia	Yes	Yes	Yes		Yes
Short stature	Yes	Yes	N/A		Yes
Microcephaly	Yes	Yes	N/A		No
Ptosis	Yes	Yes	No		Yes
Arched eyebrows	Yes	Yes	No		Yes
Hypertelorism	Yes	Yes	No		Yes
Bulbous nose	Yes	Yes	No		Yes
Low-set ears	No	Yes	No		Yes
Micrognathia	No	Yes	Yes		Yes
Low posterior hair line	Yes	Yes	No		Yes
Webbed neck	No	Yes	No		Yes
Arthrogryposis	Yes	No	No		Yes
Vertebral fusion defect	Yes	Yes	No		Yes
Scoliosis	No	Yes	Yes		Yes (High grade)
Hip deformity	No	Yes	Yes		No
Creatine kinase	Normal	Normal	Normal		Normal
Electromyography	Myopathy	N/A	N/A		N/A
Muscle biopsy	Pathologic	N/A	Pathologic		N/A
Echocardiography	N/A	N/A	Cardiomyopathy		Normal

In patient BAB7143, a homozygous missense variant in a novel gene, *VPS8*, was identified (Figure 5A). The patient had multiple joint contractures, delayed motor milestones, craniofacial dysmorphisms, and cerebellar vermis hypoplasia detected in cranial magnetic resonance imaging (MRI) (Figure 5B and Table 2). *VPS8* is one of the Vps proteins that functions in endosomal biogenesis and Golgi-to-lysosome trafficking in yeast (48, 49). Homozygous or compound heterozygous mutations in other Vps genes, *VPS33B* and *VPS53*, were previously associated with arthrogryposis–renal dysfunction–cholestasis syndrome (ARCS) type 1 (OMIM 208085) and pontocerebellar hypoplasia type 2E (PCH2E) (OMIM 615851), respectively (50, 51). Joint contractures and cerebellar anomalies were previously defined in patients with PCH2E (52). Moreover, *VPS8* has close interactions with *VPS33B* and *VPS53*, as well as *VIPAS39* (Figure 5C), and mutations of *VIPAS39* were associated with ARCS type 2 (OMIM 613404) (53). Thus, *VPS8* is a potential candidate gene for the arthrogryposis and MRI findings observed in our patient. Since the observed brain anomalies in the subject are not common findings in disorders with arthrogryposis, we further examined the exome data for an additional variant that may explain

the MRI findings, and we identified another homozygous missense variant in *POLR3A*. *POLR3A* is not a known gene for arthrogryposis, but homozygous mutations in *POLR3A* have been associated with hypomyelinating leukodystrophy-7 (HLD7) (OMIM 607694) (54). HLD7 is an autosomal recessive neurodegenerative disorder characterized by childhood onset of progressive motor decline manifest as spasticity, ataxia, tremor, cortical and cerebellar atrophy, as well as mild cognitive regression. The cerebellar component of HLD7 suggests that the identified *POLR3A* variant may have a role in the intracranial findings in this patient. The missense changes in *VPS8* and *POLR3A* both affect highly conserved valine residues on the respective proteins (Figure 5D).

In another patient (BAB7713) with arthrogryposis and cardiomyopathy findings, we identified homozygous mutations in 2 different known genes, *RIPK4* and *LMNA*. The major clinical features of the subject were contractures of hands and feet, myopathy, hypotonia, and dilated cardiomyopathy detected by echocardiogram. *RIPK4* is a known gene for popliteal pterygium syndrome type 2 (OMIM 263650), and *LMNA* mutations were reported in several allelic disorders, including dilated cardiomyo-




Figure 4. Variants in *GPR126* and *MYBPC2* identified in patient BAB6212. (A) Segregation analyses of the homozygous *GPR126* and compound heterozygous *MYBPC2* mutations in the family HOU2332. (B) Conservation alignment indicating that the affected amino acids of *MYBPC2* are conserved across different vertebrates. (C) The interaction network of *MYBPC2* (red circle) with known arthrogryposis gene products (black circles). Gray circles indicate the proteins in the same network but not associated with arthrogryposis previously.

pathy type 1A (OMIM 115200). The homozygous variant detected in *RIPK4* is a novel variant, but the *LMNA* variant has previously been reported in a patient with interstitial myocardial fibrosis (55). The identified rare homozygous variants in this subject and previously associated disorders suggest that *RIPK4* mutation is responsible for the observed joint contractures while the *LMNA* mutation may cause cardiac features and myopathy.

Patients that represent phenotypic expansion. In 3 patients, we identified novel homozygous variants in known genes; however, the clinical findings we observe in association with the newly described variant alleles suggest phenotypic expansion for trait manifestations previously attributed to this gene. In patient BAB3931, we identified a novel homozygous missense mutation in *CENPJ*, the causal gene for Seckel syndrome (SCKL) type 4 (OMIM 613676) and autosomal recessive microcephaly type 6 (MCPH-6) (OMIM 608393). Arthrogryposis is not a typical finding of SCKL type 4, but elbow-flexion contracture, hip dislocation, and talipes deformities were defined in SCKL type 1 (OMIM 210600). Moreover, Sarici et al. reported a Turkish patient with SCKL, accompanied by semilobar holoprosencephaly and arthrogryposis (56). The clinical findings of our patient overlapping with SCKL and the previously reported Turkish patient include microretrognathia, high-arched palate, crowded and decayed teeth, low-set ears, elbow-flexion contracture, ulnar

deviation of hands, talipes equinovarus, and delayed bone age measured via hand X-ray (Supplemental Figure 3). Besides these, our patient was not microcephalic, and his growth parameters were in the normal range when measured at 6 years of age, unlike typical SCKL patients. Additionally, another remarkable finding of our patient was abnormal scar formation with wound healing observed on his left foot (Supplemental Figure 3), which suggests possible connective-tissue involvement in his phenotype. Further analysis of the exome data did not reveal a reasonably plausible variant that might explain the abnormal scar formation in the patient. Clinical features of our patient overlapping with SCKL and distinct findings including arthrogryposis and abnormal wound healing suggest that the homozygous mutation of *CENPJ* observed in our patient may cause another allelic disorder apart from SCKL type 4 and MCPH-6 or may represent phenotypic expansion of *CENPJ*-related diseases.

In one male patient (BAB3955), we identified a hemizygous variant in *IDS*, which is a known gene for mucopolysaccharidosis type 2 (MPS2) (OMIM 309900). MPS2 is an X-linked metabolic disorder caused by deficiency of the lysosomal enzyme iduronate sulfatase that leads to progressive accumulation of glycosaminoglycans in nearly all cell types. The typical clinical features include severe airway obstruction; skeletal deformities, including joint contractures; cardiomyopathy; and neurologic decline (57). The




Figure 5. Homozygous *VPS8* and *POLR3A* variants identified in BAB7143. (A) Segregation analyses of the WES-detected variants. The proband was homozygous, and the parents were heterozygous carriers, consistent with Mendelian expectations. (B) Patient photographs showing clinical features, including ptosis, joint contractures, ulnar deviation of the hands, and surgically repaired foot deformity. (C) The interaction network of *VPS8* (red circle) with other gene products, such as *VPS33B*, *VPS53*, and *VIPAS39* (black circles), which were previously associated with different arthrogryposis-related disorders. Gray circles indicate the proteins in the same network but not associated with arthrogryposis previously. (D) Peptide alignment showing the conservation of the affected amino acids across the species.

overlapping findings of our patient with MPS2 were delayed neuromotor development, growth retardation, seizures, laryngomalacia, flexion contractures of hands, and hepatosteatosis. However, our patient did not present with some other typical clinical manifestations of MPS2, such as coarse facies and macrocephaly, and he was clinically diagnosed with spinal muscular atrophy due to decreased intrauterine fetal movements and anterior horn cell involvement of spinal cord detected in EMG. Therefore, the enzymatic analysis to confirm MPS2 was not performed during the patient followup. Because the patient died at 1.5 years of age, we suggest that clinical evidence for MPS2 may not have yet developed or that the identified mutation may have resulted in phenotypic expansion in the patient.

We identified a homozygous novel variant in *GBE1* in patient BAB3960. The mutations in *GBE1* were previously associated with glycogen storage disease type 4 (GSD4) (OMIM 232500). Glycogen branching enzyme deficiency is causative of GSD4 that is characterized by the accumulation of polyglucosan in almost all tissues. Clinical features of the typical GSD4 are failure to thrive,

hepatosplenomegaly, and liver cirrhosis leading to death in early childhood (58). However, GSD4 can show extreme clinical heterogeneity, and different clinical manifestations may present, such as nonprogressive hepatic form and neuromuscular forms. Arthrogryposis is one of the characteristic findings of the congenital neuromuscular form of GSD4, which is mostly seen with hydrops fetalis and perinatal death. There are also juvenile and adult neuromuscular forms that are dominated by myopathy, and the classic clinical manifestation of liver cirrhosis generally is not present in these neuromuscular forms (59–61). The diagnosis of GSD4 can be confirmed by the determination of the branching enzyme activity in affected tissues. However, the commonly used assays are indirect and not sensitive enough for accurate evaluation of low levels of branching activity (60, 62). In our 2-year-old male patient, the presence of joint contractures was compatible with the congenital neuromuscular form, but the clinical manifestation was not severe. Additional patient findings suggesting phenotypic expansion were cleft palate, pterygium colli, pelviclectasis, cryptorchidism, and tall vertebral bodies detected on X-ray, which, to




Figure 6. Variants in *FBN3* identified in BAB7826. (A) Family pedigree and segregation results of the identified compound heterozygous variants in *FBN3*. (B) Patient photographs showing the representative clinical sign of arthrogryposis.

the best of our knowledge, were not reported in GSD4 patients previously. Also, the general hypotonia detected in the subject was compatible with the juvenile form. We suggest that our data support the clinical heterogeneity of GSD4 and expand the phenotypic spectrum with the novel clinical findings.

Patients with rare deleterious variants in a single novel candidate gene. We identified compound heterozygous variants in *FBN3* in patient BAB7826 (Figure 6A). The subject had multiple joint contractures with severely affected elbows and knees (Figure 6B). *FBN3* is one of the fibrillin genes that function in the structural architecture of connective tissues; mutations of *FBN3* have not been reported in any Mendelian disorder. Other fibrillin genes, *FBN1* and *FBN2*, were previously associated with disorders comprising arthrogryposis, but *FBN3* was not. Mutations of *FBN1* were described in autosomal dominant Weill-Marchesani syndrome (OMIM 277600), and *FBN2* mutations are associated with DA type 9, also known as Beals syndrome (OMIM 121050). Our data lead us to speculate that mutations of *FBN3* may also cause arthrogryposis, as found for other fibrillin gene mutations.

The exome analysis of BAB6499 revealed 2 heterozygous variants in *MYO9A*, one of which is de novo and the other inherited from the mother (Figure 7A). The subject had DA with predominant involvement of the fingers and feet (Figure 7B). Mutations of *MYO9A* were not previously associated with any human disease. *MYO9A* is one of the unconventional myosins that are members of the myosin superfamily that display the general domains of conventional myosins (63, 64). In a mouse study, Northern blot

analysis detected mouse *Myo9a* expression in limb buds, and *in situ* hybridization to limb buds suggested that *Myo9a* may be localized to the precartilagenous mesenchyme (65). Also in the same study, *Myo9a* was shown to be expressed in the skeletal and the nervous systems, 2 important systems where dysfunction may play a role in the formation of arthrogryposis and consistent with the hypothesis that mutations of *MYO9A* may cause arthrogryposis. Moreover, the mutated amino acids Gly2282 and Tyr203 are highly conserved in vertebrates (Figure 7C), and *MYO9A* has interactions with some other myosins that have previously been associated with arthrogryposis disorders (Figure 7D). The segregation pattern of identified variants in our patient suggests that deleterious de novo mutations or compound heterozygous mutations of *MYO9A* may cause arthrogryposis.

In family HOU2061 with 8 affected individuals diagnosed with APS, we applied WES to 3 affected cousins, and a heterozygous variant in *PSD3* was detected and shown to cosegregate with autosomal dominant arthrogryposis. To confirm this identified variant, we analyzed 12 individuals from 4 generations in the pedigree with available DNA (8 affected, 4 unaffected) by Sanger sequencing. We observed that all affected individuals were carriers for the same mutation, while the unaffected kindred were normal for the same allele (Figure 8A). Additionally, we calculated the logarithm of odds (LOD) score, and we found that, based on the family size, our data ($\theta = 0$, LOD score = 1.806) supports the potential linkage of *PSD3* to the phenotype. The function of *PSD3* is not well established, and mutations of *PSD3* were not reported in any Mendelian disorder; however, the association of *PSD3* with systemic sclerosis—which is a heterogeneous disorder characterized by extensive skin fibrosis, microvascular changes, and autoimmunity—was reported (66). The skin fibrosis component of systemic sclerosis might be a clue for explaining the phenotype observed in APS patients with *PSD3* mutation by reason of the fact that the main phenotype observed in APS is skin webbing around the elbow joint (Figure 8B). Nevertheless, the biological mechanism underlying APS and molecular pathway of *PSD3* needs to be investigated further.

In summary, beside the known and novel variants in known genes, we identified variants in 5 potential novel candidate genes (*FBN3*, *MYBPC2*, *MYO9A*, *PSD3*, and *VPS8*) in patients with different arthrogryposis subtypes. Three of 5 novel genes were observed as a single causal gene, while variants in 2 novel candidate genes were identified as a second locus in addition to a known gene that may affect the phenotype with a mutational load or may cause a blended phenotype. Moreover, we identified a potential mutational burden in 6 patients with homozygous or compound heterozygous mutations in 2 different known genes. In 4 of 6 patients, both identified genes were previously associated with an arthrogryposis disorder, and the mutational burden may have contributed to the clinical severity observed (38); meanwhile, in 2 of 6 patients, the identified genes—in addition to known arthrogryposis genes—were associated with different disorders without arthrogryposis and resulted in an apparent blended phenotype with clinical manifestations of both disorders (40, 67). Arthrogryposis is observed in a broad group of genetically heterogeneous disorders with unknown molecular etiology in the considerable majority. In our study, the WES method enabled us to investigate potential oligogenic or mutational burden models, as well as to




Figure 7. MYO9A variants identified in BAB6499. (A and B) Segregation analyses of the identified *MYO9A* variants and patient photographs. While c.608A>G variant is inherited from the mother, c.6845G>A variant is observed as de novo. (C) Peptide alignment of human *MYO9A* with *MYO9A* in other species. Gly2282 and Tyr203 are conserved residues across all vertebrates. (D) Interactome of *MYO9A* (red circle) that shows the interactions with known arthrogryposis gene products (black circles). Gray circles indicate the proteins in the same network but not associated with arthrogryposis previously.

identify novel candidate genes in arthrogryposis patients. We suggest that using genomic sequencing methods in patient populations with arthrogryposis disorders may identify novel arthrogryposis genes and provide further molecular etiological insights into this phenotype, as well as provide opportunities to uncover novel genetic mechanisms, including potential contributions of multilocus variation.

Methods

Human subjects and sample collection. Fifty-one Turkish patients and 1 Arab patient with arthrogryposis were evaluated by 1 or more pediatricians and/or clinical geneticists. Genomic DNA was extracted from whole blood using the Gentra Puregene Blood Extraction Kit per the manufacturer's protocol (QIAGEN). All the genomic studies were performed on the DNA samples extracted from whole blood.

WES and data analysis. Samples from all patients underwent WES at Baylor College of Medicine Human Genome Sequencing Center through the Baylor-Hopkins Center for Mendelian Genomics research initiative. Genomic DNA samples obtained from patients processed

according to protocols previously described (68). Briefly, DNA sample was prepared into Illumina paired-end libraries and underwent whole-exome capture using BCM-HGSC core design (52 Mb, NimbleGen, Roche Sequencing), followed by sequencing on the Illumina HiSeq 2000 platform with an approximately 150× depth of coverage. Data produced was aligned and mapped to the human genome reference sequence (hg19) using the Mercury pipeline. Variants were called using the ATLAS (an integrative variant analysis pipeline optimized for variant discovery) variant calling method and SAMtools (The Sequence Alignment/Map) and annotated using the in-house-developed Cassandra annotation pipeline that uses ANNOVAR (<http://annovar.openbioinformatics.org/en/latest/>) (69–71).

The findings of WES studies were deposited into the NCBI's database of Genotypes and Phenotypes (dbGaP) archive (phs000711.v3.p1) (<http://www.ncbi.nlm.nih.gov/gap/>).

PCR validation and segregation analyses. To confirm the identified WES-detected variant, we applied Sanger sequencing following PCR amplification, and segregation analyses were performed on all DNA-available members of the families. Same pairs of primers are




Figure 8. PSD3 variant showing an autosomal dominant inheritance identified in the patients with APS. (A) Sanger sequencing analysis showing the segregation result of *PSD3* variant identified in family HOU2061. **(B)** Elbow photographs of the affected individuals.

utilized for both PCR amplification and Sanger sequencing. PCR reactions were performed following the protocols for HotStarTaq DNA Polymerase (QIAGEN).

AOH and copy number variation (CNV) analysis. To examine AOH regions surrounding candidate variants, we calculated B-allele frequency using WES data as a ratio of variant reads to total reads. These data were then processed using the circular binary segmentation algorithm to identify AOH regions (72).

To identify heterozygous CNVs, we used WES data. WES data were processed using CoNIFER software (73) and HMZDelFinder (<https://github.com/BCM-Lupskilab/HMZDelFinder>). HMZDelFinder is an in-house-developed algorithm implemented in the R programming language (R Core Team 2014, <http://www.R-project.org>). First, for every individual, we computed the total number of reads in each exon and normalized read-depth values (reads per kilobase per million [RPKM] mapped reads) using the utility provided with CoNIFER (73). Next, we identified homozygous deletions by analyzing exons for which the RPKM value was lower than 0.5. Then, low-quality samples (5% of individuals with the highest number of deletions) were removed. Next, low-quality/common deletions were removed—if the frequency of a

particular homozygous/hemizygous deletion was $\geq 0.5\%$ in the whole cohort—and calls from consecutive exons were merged.

RPKM thresholds were determined based on the analysis of distribution of RPKM values in previously identified and confirmed homozygous deletions. Finally, we filtered out homozygous CNVs that did not overlap with larger (≥ 1 Kb) AOH regions. RPKM values were also used for further visualization of detected deletions.

Interaction network analysis. As a part of our approach to identify novel candidate genes, we performed interaction network analyses. The predicted interaction network had been based on 6 data sources, including coexpression, colocalization, pathways, physical interactions, predicted interactions, and shared protein domain data sources. Being predicted to be included in a potential interaction network with known disease genes may further support the novel gene association with the disease.

Study approval. This study was approved by the Institutional Review Board at Baylor College of Medicine. Informed consent was obtained from all subjects prior to enrollment in the project. Additionally, written consent was obtained from patients or patients' parents to publish patient photos.

Author contributions

YB participated in study design, analyzed the WES data, and wrote the manuscript. EK, TH, and DP contributed to clinical assessment of the patients and WES analyses. ZCA and TG participated in computational and bioinformatics design and analysis. ZCA performed copy number variation and interaction network analyses. EOY, GAT, HA, DT, STB, AG, SI, AWEH, WLC, AK, TC, OYO, TY, IAB, NE, and BT participated in clinical evaluation of the patients and sample collection. MMA participated in DNA extraction, PCR validation, and figure production for the manuscript. SNJ, DMM, EB, and RAG organized the WES data analyses. JRL participated in study design, data organization, management and analyses, and writing of the manuscript. All coauthors reviewed the manuscript.

Acknowledgments

We thank the patients and their families who participated in this study. This work was supported in part by US NHGRI/NHLBI grant U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics and US NINDS grant R01NS058529 to J.R. Lupski. W.L. Charng is supported by CPRIT training Program RP140102, and T. Harel is supported by the T32 GM07526 Medical Genetics Research Fellowship Program.

Address correspondence to: James R. Lupski, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Room 604B, Houston, Texas 77030, USA. Phone: 713.798.3723; E-mail: jlupski@bcm.edu.

1. Lowry RB, Sibbald B, Bedard T, Hall JG. Prevalence of multiple congenital contractures including arthrogryposis multiplex congenita in Alberta, Canada, and a strategy for classification and coding. *Birth Defects Res A Clin Mol Teratol.* 2010;88(12):1057–1061.
2. Hall JG. Arthrogryposis (multiple congenital contractures): diagnostic approach to etiology, classification, genetics, and general principles. *Eur J Med Genet.* 2014;57(8):464–472.
3. Filges I, Hall JG. Failure to identify antenatal multiple congenital contractures and fetal akinesia—proposal of guidelines to improve diagnosis. *Prenat Diagn.* 2013;33(1):61–74.
4. Haliloglu G, Topaloglu H. Arthrogryposis and fetal hypomobility syndrome. *Handb Clin Neurol.* 2013;113:1311–1319.
5. Bamshad M, Jorde LB, Carey JC. A revised and extended classification of the distal arthrogryposes. *Am J Med Genet.* 1996;65(4):277–281.
6. Hall JG, Reed SD, Greene G. The distal arthrogryposes: delineation of new entities—review and nosologic discussion. *Am J Med Genet.* 1982;11(2):185–239.
7. Beals RK. The distal arthrogryposes: a new classification of peripheral contractures. *Clin Orthop Relat Res.* 2005;435:203–210.
8. Oldfors A. Hereditary myosin myopathies. *Neuromuscul Disord.* 2007;17(5):355–367.
9. Toydemir RM, Rutherford A, Whitby FG, Jorde LB, Carey JC, Bamshad MJ. Mutations in embryonic myosin heavy chain (MYH3) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. *Nat Genet.* 2006;38(5):561–565.
10. Gurnett CA, et al. Myosin binding protein C1: a novel gene for autosomal dominant distal arthrogryposis type 1. *Hum Mol Genet.* 2010;19(7):1165–1173.
11. Sung SS, et al. Mutations in genes encoding fast-twitch contractile proteins cause distal arthrogryposis syndromes. *Am J Hum Genet.* 2003;72(3):681–690.
12. Sung SS, Brassington AM, Krakowiak PA, Carey JC, Jorde LB, Bamshad M. Mutations in TNNT3 cause multiple congenital contractures: a second locus for distal arthrogryposis type 2B. *Am J Hum Genet.* 2003;73(1):212–214.
13. McMillin MJ, et al. Mutations in ECEL1 cause distal arthrogryposis type 5D. *Am J Hum Genet.* 2013;92(1):150–156.
14. Dieterich K, et al. The neuronal endopeptidase ECEL1 is associated with a distinct form of recessive distal arthrogryposis. *Hum Mol Genet.* 2013;22(8):1483–1492.
15. Vogt J, et al. CHRNG genotype-phenotype correlations in the multiple pterygium syndromes. *J Med Genet.* 2012;49(1):21–26.
16. Kawira EL, Bender HA. An unusual distal arthrogryposis. *Am J Med Genet.* 1985;20(3):425–429.
17. McKeown CM, Harris R. An autosomal dominant multiple pterygium syndrome. *J Med Genet.* 1988;25(2):96–103.
18. Prontera P, Sensi A, Merlo L, Garani G, Cocchi G, Calzolari E. Familial occurrence of multiple pterygium syndrome: expression in a heterozygote of the recessive form or variability of the dominant form? *Am J Med Genet A.* 2006;140(20):2227–2230.
19. Hoffmann K, et al. Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit. *Am J Hum Genet.* 2006;79(2):303–312.
20. Morgan NV, et al. Mutations in the embryonal subunit of the acetylcholine receptor (CHRNG) cause lethal and Escobar variants of multiple pterygium syndrome. *Am J Hum Genet.* 2006;79(2):390–395.
21. Michalk A, et al. Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders. *Am J Hum Genet.* 2008;82(2):464–476.
22. McKie AB, et al. Germline mutations in RYR1 are associated with foetal akinesia deformation sequence/lethal multiple pterygium syndrome. *Acta Neuropathol Commun.* 2014;2(1):148.
23. Chong JX, et al. Autosomal-Dominant Multiple Pterygium Syndrome Is Caused by Mutations in MYH3. *Am J Hum Genet.* 2015;96(5):841–849.
24. Hall JG. Arthrogryposis multiplex congenita: etiology, genetics, classification, diagnostic approach, and general aspects. *J Pediatr Orthop B.* 1997;6(3):159–166.
25. Narkis G, Landau D, Manor E, Ofir R, Birk OS. Genetics of arthrogryposis: linkage analysis approach. *Clin Orthop Relat Res.* 2007;456:30–35.
26. Hunter JM, et al. Review of X-linked syndromes with arthrogryposis or early contractures—aid to diagnosis and pathway identification. *Am J Med Genet A.* 2015;167A(5):931–973.
27. Drury S, et al. A novel homozygous ERCC5 truncating mutation in a family with prenatal arthrogryposis—further evidence of genotype-phenotype correlation. *Am J Med Genet A.* 2014;164A(7):1777–1783.
28. Fukumura S, et al. Compound heterozygous GFM2 mutations with Leigh syndrome complicated by arthrogryposis multiplex congenita. *J Hum Genet.* 2015;60(9):509–513.
29. Ravenscroft G, et al. Mutations of GPR126 are responsible for severe arthrogryposis multiplex congenita. *Am J Hum Genet.* 2015;96(6):955–961.
30. Wilbe M, et al. MuSK: a new target for lethal fetal aknesia deformation sequence (FADS). *J Med Genet.* 2015;52(3):195–202.
31. Tan-Sindhunata MB, et al. Identification of a Dutch founder mutation in MUSK causing fetal aknesia deformation sequence. *Eur J Hum Genet.* 2014;23(9):1151–1157.
32. Alazami AM, et al. A novel syndrome of Klippel-Feil anomaly, myopathy, and characteristic facies is linked to a null mutation in MYO18B. *J Med Genet.* 2015;52(6):400–404.
33. Pagnamenta AT, et al. Germline recessive mutations in PI4KA are associated with perisylvian polymicrogyria, cerebellar hypoplasia and arthrogryposis. *Hum Mol Genet.* 2015;24(13):3732–3741.
34. Fusco C, Frattini D, Salerno GG, Canali E, Bernasconi P, Maggi L. New phenotype and neonatal onset of sodium channel myotonia in a child with a novel mutation of SCN4A gene. *Brain Dev.* 2015;37(9):891–893.
35. Rienhoff HY Jr, et al. A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome. *Am J Med Genet A.* 2013;161A(8):2040–2046.
36. Laquerriere A, et al. Mutations in CNTNAP1 and ADCY6 are responsible for severe arthrogryposis multiplex congenita with axoglial defects. *Hum Mol Genet.* 2014;23(9):2279–2289.
37. Graham JM Jr, et al. Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy. *Am J Hum Genet.* 2001;69(2):291–300.
38. Gonzaga-Jauregui C, et al. Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy. *Cell Rep.* 2015;12(7):1169–1183.

39. Esposito T, et al. Digenic mutational inheritance of the integrin alpha 7 and the myosin heavy chain 7B genes causes congenital myopathy with left ventricular non-compact cardiomyopathy. *Orphanet J Rare Dis.* 2013;8:91.
40. Yang Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA.* 2014;312(18):1870–1879.
41. Demir E, et al. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. *Am J Hum Genet.* 2002;70(6):1446–1458.
42. Neveling K, et al. Mutations in BICD2, which encodes a golgin and important motor adaptor, cause congenital autosomal-dominant spinal muscular atrophy. *Am J Hum Genet.* 2013;92(6):946–954.
43. Markus B, Narkis G, Landau D, Birk RZ, Cohen I, Birk OS. Autosomal recessive lethal congenital contractural syndrome type 4 (LCCS4) caused by a mutation in MYBPC1. *Hum Mutat.* 2012;33(10):1435–1438.
44. Ha K, et al. MYBPC1 mutations impair skeletal muscle function in zebrafish models of arthrogryposis. *Hum Mol Genet.* 2013;22(24):4967–4977.
45. Dagoneau N, et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. *Am J Hum Genet.* 2004;74(2):298–305.
46. Golomb E, et al. Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family. *J Biol Chem.* 2004;279(4):2800–2808.
47. Choi BO, et al. A complex phenotype of peripheral neuropathy, myopathy, hoarseness, and hearing loss is linked to an autosomal dominant mutation in MYH14. *Hum Mutat.* 2011;32(6):669–677.
48. Carim L, Sumoy L, Andreu N, Estivill X, Escarceler M. Cloning, mapping and expression analysis of VPS33B, the human orthologue of rat Vps33b. *Cytogenet Cell Genet.* 2000;89(1-2):92–95.
49. Epp N, Ungermann C. The N-terminal domains of Vps3 and Vps8 are critical for localization and function of the CORVET tethering complex on endosomes. *PLoS One.* 2013;8(6):e67307.
50. Gissen P, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. *Nat Genet.* 2004;36(4):400–404.
51. Feinstein M, et al. VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). *J Med Genet.* 2014;51(5):303–308.
52. Ben-Zeev B, et al. Progressive cerebellocerebral atrophy: a new syndrome with microcephaly, mental retardation, and spastic quadriplegia. *J Med Genet.* 2003;40(8):e96.
53. Cullinane AR, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. *Nat Genet.* 2010;42(4):303–312.
54. Bernard G, et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. *Am J Hum Genet.* 2011;89(3):415–423.
55. Fontana M, et al. CMR-verified interstitial myocardial fibrosis as a marker of subclinical cardiac involvement in LMNA mutation carriers. *JACC Cardiovasc Imaging.* 2013;6(1):124–126.
56. Sarici D, Akin MA, Kara A, Doganay S, Kurtoglu S. Seckel syndrome accompanied by semilobar holoprosencephaly and arthrogryposis. *Pediatr Neurol.* 2012;46(3):189–191.
57. Wraith JE, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. *Eur J Pediatr.* 2008;167(3):267–277.
58. Andersen DH. Familial cirrhosis of the liver with storage of abnormal glycogen. *Lab Invest.* 1956;5(1):11–20.
59. Tang TT, et al. Neonatal hypotonia and cardiomyopathy secondary to type IV glycogenosis. *Acta Neuropathol.* 1994;87(5):531–536.
60. Bruno C, Cassandrini D, Assereto S, Akman HO, Minetti C, Di Mauro S. Neuromuscular forms of glycogen branching enzyme deficiency. *Acta Myol.* 2007;26(1):75–78.
61. Goebel HH, et al. Adult polyglucosan body myopathy. *J Neuropathol Exp Neurol.* 1992;51(1):24–35.
62. Moses SW, Parvari R. The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. *Curr Mol Med.* 2002;2(2):177–188.
63. Bahler M. Myosins on the move to signal transduction. *Curr Opin Cell Biol.* 1996;8(1):18–22.
64. Mooseker MS, Cheney RE. Unconventional myosins. *Annu Rev Cell Dev Biol.* 1995;11:633–675.
65. Gorman SW, et al. The cloning and developmental expression of unconventional myosin IXA (MYO9A) a gene in the Bardet-Biedl syndrome (BBS4) region at chromosome 15q22-q23. *Genomics.* 1999;59(2):150–160.
66. Jin J, Chou C, Lima M, Zhou D, Zhou X. Systemic sclerosis is a complex disease associated mainly with immune regulatory and inflammatory genes. *Open Rheumatol J.* 2014;8:29–42.
67. Yang Y, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N Engl J Med.* 2013;369(16):1502–1511.
68. Lupski JR, et al. Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy. *Genome Med.* 2013;5(6):57.
69. Li H, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* 2009;25(16):2078–2079.
70. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010;38(16):e164.
71. Bainbridge MN, et al. Whole-genome sequencing for optimized patient management. *Sci Transl Med.* 2011;3(87):87re3.
72. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. *Biostatistics.* 2004;5(4):557–572.
73. Krumm N, et al. Copy number variation detection and genotyping from exome sequence data. *Genome Res.* 2012;22(8):1525–1532.